Paul Tudor Jones’s Arcutis Biotherapeutics ARQT Stock Holding History

Paul Tudor Jones’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.46M	Buy	+131,914	New	+$3.07M	﹤0.01%	1541
2026 Q1	–	Sell	-106,134	Closed	-$3.08M	–	3578
2025 Q4	$3.08M	Buy	106,134 +36,154	+52%	+$926K	0.01%	1487
2025 Q3	$1.32M	Buy	+69,980	New	+$1.1M	﹤0.01%	2077
2025 Q2	–	Sell	-103,373	Closed	-$1.62M	–	3217
2025 Q1	$1.62M	Buy	103,373 +39,039	+61%	+$550K	0.01%	1489
2024 Q4	$896K	Buy	64,334 +43,370	+207%	+$475K	﹤0.01%	1806
2024 Q3	$195K	Buy	+20,964	New	+$207K	﹤0.01%	2544
2024 Q2	–	Sell	-204,779	Closed	-$2.03M	–	2299
2024 Q1	$2.03M	Buy	+204,779	New	+$1.53M	0.01%	1016
2023 Q4	–	Sell	-45,461	Closed	-$241K	–	2349
2023 Q3	$241K	Buy	+45,461	New	+$387K	﹤0.01%	2018
2023 Q2	–	Sell	-30,306	Closed	-$333K	–	2405
2023 Q1	$333K	Buy	+30,306	New	+$438K	0.01%	1857
2022 Q4	–	Sell	-18,349	Closed	-$351K	–	2357
2022 Q3	$351K	Buy	+18,349	New	+$416K	0.01%	1671

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Paul Tudor Jones's ARQT Position: Q2 2026 in Review

Paul Tudor Jones opened a new position in Arcutis Biotherapeutics (ARQT) in Q2 2026: 131,914 shares worth $3.46M. The stake represents ﹤0.01% of the portfolio and ranks #1541 among its holdings. This is a return to the name: Paul Tudor Jones previously reported a position in ARQT as recently as Q4 2025.

Paul Tudor Jones first reported a position in ARQT in Q3 2022 and has held it in 10 quarters since. 271 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

Paul Tudor Jones held 131,914 shares of Arcutis Biotherapeutics worth $3.46M as of Q2 2026.
Arcutis Biotherapeutics was a new Paul Tudor Jones position in Q2 2026.
Arcutis Biotherapeutics made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #1541 holding.
Paul Tudor Jones first reported a position in Arcutis Biotherapeutics in Q3 2022 and has held it in 10 quarters since.
271 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.